[1]Hershfield MS. PEG-ADA-An alternative to haploidentical bone-marrow transplantation and an adjunct to gene-therapy for adenosine-deaminase deficiency[J].Hum Mutat,1995, 5(2): 107～112. [2]Hershfield MS. PEG-ADA replacement therapy for adenosine-deaminase deficiency-an update after 8.5 years[J].Clin Immunol Immunopathol,1995,76(3):s228～s232. [3]Ashihaya Y,Kono T,Yamazaki S,et al. Modification of E. coli L-Asparaginase with polyethylene glycol: disappearance of binding ability to anti-asparaginase serum[J].Biochem Biophys Res Commun,1978,83(2):385. [4]周笑艳, 刘景晶. 聚乙二醇对大肠杆菌L-天冬酰胺酶的化学修饰[J]. 中国药科大学学报, 2000, 31(3): 230～233. [5]曹淑桂, 田浩, 赵秋宇等. 几种因素在L-天冬酰胺酶化学修饰中对酶活力及抗原性的影响[J]. 药学学报, 1990, 25(10): 732. [6]夏曙辉译编. 抗肿瘤药Pegaspargase[J].中国新药杂志, 1996, 5(4): 316. [7]Holle LM. Pegaspargase: An alternative[J]. Ann Pharmacother, 1997, 31(5): 616～624. [8]Sekine T, Kodera Y, Saito T,et al.L-asparaginase modified by poly (ethylene glycol) derivative with a comb-shaped form-antitumor-activity and induction of immune tolerance[J].Biomed Res,1995, 16: 121. [9]Kodera Y, Sekine T, Yasukohchi T,et al.Stabilization of L-asparaginase modified with comb-shaped poly (ethylene glycol) derivatives,in vivo and in vitro[J].Bioconjugate Chem,1994,5:283. [10]Katre NV, Knauf MJ,Laird WJ.Chemical modification of recombinant interleukin 2 by polyethylene glycol increases its potency in murine Meth A sarcoma model[J].Proc Natl Acad Sci USA,1987,84:1487. [11]王立夫, 吴裕忻, 章永平等. rIL-2的聚乙二醇修饰物的制备及其体内外抗肝癌细胞作用[J]. 肿瘤, 1997, 17(5): 349～352. [12]郑宝胜, 徐明波, 沈倍奋. 重组人白介素-2的化学修饰. 军事医学科学院院刊[J], 1994, 18(1): 60. [13]冯学胜, 汤钊猷, 刘康达，等.聚乙二醇修饰的rIL-2体内抗小鼠肝癌活性的研究[J]. 中华肿瘤杂志, 1993, 16(4): 256. [14]Goodson RJ, Katre NV. Site-directed PEGylation of recombinant interleukin-2 at its glycosylation site[J]. Bio/Technol,1990, 8(4):343. [15]Tsutsumi Y, Tsunoda SI, Kamada H,et al. PEGylation of interleukin-6 effectively increases its thrombopoietic po-tency[J].Thromb Haemost,1997, 77:168～173. [16]Tsutsumi Y, Kihira T, Tsunoda S,et al. Molecular design of hybrid tumour necrosis factor alpha with polyethylene glycol increases its anti-tumour potency[J].Br J Cancer,1995, 71: 963～968. [17]Tsunoda S, Ishikawa T, Yamamoto Y,et al. Enhanced antitumor potency of polyethylene glycolylated tumor necrosis factor-α: A novel polymer-conjugation technique with a reversible amino-protective reagent[J].J Pharmacol Exp Ther, 1999, 290: 368～372. [18]Sharon B, Nadine T, Tomoaki I,et al. Relationship between molecular mass and duration of activity of polyethylene glycol conjugated granulocyte colony-stimmulating factor mutein[J].Exp Hematol,1999, 27: 425～432. [19]Niven RW, Whitcomb KL, Shaner L,et al. Pulmonary absorption of polyethylene glycolated recombinant human granulocyte-colony-stimulating factor (PEG-rhG-CSF)[J].J Controlled Release,1994,32:177～189. [20]Knusli C, Delgado C, Malik F,et al. polyethylene-glycol (PEG) modification of granulocyte-macrophage colony stimulating factor (GM-CSF) enhances neutrophil priming activity but not colony stimulating activity[J].Br J Hae-matol，1992, 82(4): 654～663. [21]Malik F, Brew J, Maidment SA,et al. PEG-modified erythropoietin with improved efficacy[J].Abstra/Exp Hematol，2000,28:106. [22]Harker LA, Marzec UM, Novembre F,et al. Treatment of thrombocytopenia in chimpanzees infected with human immunodeficiency virus by pegylated recombinant human megakaryocyte growth and development factor[J].Blood,1997,90:754. [23]Guerra PI, Acklin C, Kosky AA,et al. PEGylation prevents the N-terminal degradation of megakaryocyte growth and development factor[J].Pharm Res，1998, 15: 1822～1827. [24]Beauchamp CO, Gonias SL, Menapace DP,et al. A new procedure for the synthesis of polyethylene glycol-protein adducts; effects on function, receptor recognition, and clearance of superoxide dismutase, lactoferrin, and α2-macroglobulin[J].Anal Biochem,1983, 131: 25. [25]区耀华, 吕冬, 周昕. 超氧化物歧化酶化学修饰的初步研究[J]. 生物化学和生物物理进展, 1989, 16(3): 203. [26]王继华, 曹淑桂, 程玉华. 双链聚乙二醇与超氧化物歧化酶共价结合物的理化和免疫学性质[J]. 生物化学和生物物理进展, 1992, 19(6): 444. [27]杨保珍, 张天民. 长效低抗原性超氧化物歧化酶的研制及其药物动力学[J]. 中国医药工业杂志, 1991, 22(11): 526. [28]洛训懿, 王晶翼. 重组人超氧化物歧化酶化学修饰的初步研究[J]. 生物化学与生物物理进展, 1993, 20(6): 452. [29]Ladd DL,Snow RA. Reagents for the preparation of chromophorically labeled polyethylene glycol-protein conjugates[J].Anal Biochem, 1993, 210: 258. [30]Humphries J, Lattimer C, Smith A,et al. High and constant plasma levels of tissue plasminogen activator and PEG-hirudin can be achieved by subcutaneous delivery[J].Thromb Res, 1997,87:123～129. [31]Esslinger HU, Haas S, Maurer R,et al. Pharmacodynamic and safety results of PEG-hirudin in healthy volunteers [J].Thromb Haemost, 1997, 77: 911～919. [32]Kajihara J, Shibata K, Nakano Y,et al. Physicochemical characterization of PEG-PPG conjugated human urokinase[J]. Biochim Biophys Acta,1994, 1199(2): 202～208. [33]叶建新, 肖成祖, 张正光，等.聚乙二醇修饰对尿激酶原性质的影响[J]. 军事医学科学院院刊, 1996, 20: 110～112. [34]Ajisaka K,Iwashita Y. Modification of human hemoglobin with polyethylene glycol: A new candidate for blood substitute[J]. Biochem.Biophys Res Comm, 1980, 97: 1076. [35]洪民, 宋文俊. 聚乙二醇大分子化猪血红蛋白对其携氧特性的影响[J]. 生物工程学报, 2000, 16(1): 22～26. [36]Tang W, Chang Y, Xu LF. Studies on the PEGylation of protein at a specific site: Sulfhydryl-PEGylation of 97Cys-IFN-gamma[J].Acta Biochim Biophys Sin,1996, 28: 312～315 [37]Algranati NE, Sy S, Modi M. A branched methoxy 40 KDA polyethylene glycol (PEG) moiety optimizes the pharmacokinetics (PK) of peginterferon alpha-2A (PEG-IFN) and may explain its enhanced efficacy in chronic hepatitis C (CHC)[J].Hepatology,1999, 30: 120. [38]Zeuzem S, Feinman SV, Rasenack J,et al. Peginterferon alfa-2a in patients with chronic hepatitis C[J].N Engl J Med,2000, 343(23): 1666～1672. [39]Heathcote EJ, Shiffman ML, Cooksley WGE,et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis[J].N Engl J Med, 2000, 343(23): 1673-1680. [40]姚文兵, 吴梧桐, 沈子龙，等. 聚乙二醇对干扰素-α-2b的初步化学修饰研究[J]. 中国药科大学学报, 2000, 31(1): 74～77.